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Abstract
Background Recently, the anti-sense oligonucleotide drug nusinersen was approved for spinal muscular atrophy (SMA) and 
our aim was to find a response marker for this treatment.
Methods Twelve children with SMA type 1 and two copies of the SMN2 gene were included in a consecutive single-center 
study. The children were sampled for CSF at baseline and every time nusinersen was given intrathecally. The neuronal bio-
markers NFL and tau and the glial biomarker GFAP were measured. Motor function was assessed using CHOP INTEND. 
Eleven similarly aged children, who were investigated to rule out neurological or infectious disease, were used as controls.
Results Baseline levels of NFL (4598 ± 981 vs 148 ± 39, P = 0.001), tau (939 ± 159 vs 404 ± 86, P = 0.02), and GFAP 
(236 ± 44 vs 108 ± 26, P = 0.02) were significantly higher in SMA children than controls. Motor function improved by nusin-
ersen treatment in median 13 points corresponding to 5.4 points per month of treatment (P = 0.001). NFL levels typically 
normalized ( < 380 pg/ml) between the fourth and fifth doses [− 879.5 pg/mL/dose, 95% CI (− 1243.4, − 415.6), P = 0.0001], 
tau levels decreased [− 112.6 pg/mL/dose, 95% CI (− 206–7, − 18.6), P = 0.01], and minor decreases in GFAP were observed 
[− 16.9 pg/mL/dose, 95% CI (− 22.8, − 11.2), P = 0.02] by nusinersen treatment. Improvement in motor function correlated 
with reduced concentrations of NFL (rho = − 0.64, P = 0.03) and tau (rho = − 0.85, P = 0.0008) but not GFAP.
Conclusions Nusinersen normalized the axonal damage marker NFL and correlated with motor improvement in children 
with SMA. NFL may, therefore, be a novel biomarker to monitor treatment response early in the disease course.
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Introduction
Spinal muscular atrophy (SMA) is an autosomal recessive 
disease that causes degeneration of spinal cord motor neu-
rons resulting in hypotonia and muscle weakness [1]. The 
carrier frequency of SMA is one in 50 and the incidence is 
one in 10,000. The most severe form of the disease is SMA 
type one (SMA1; approximately 50% of affected children), 
which is characterized by an onset before 6 months of age 
and a life expectancy of less than 2 years [1]. Children with 
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SMA type two (SMA2) have a milder form of the disease, 
with an onset between 6 and 18 months of age, can sit with-
out support, and a few can stand with leg braces, but none 
can walk independently. Difficulty in swallowing and cough-
ing and respiratory insufficiency may occur during adoles-
cence for individuals with SMA2. Patients with SMA type 
three (SMA3) have onset of disease after 18 months. They 
learn to walk, although some require wheelchair assistance 
later in life; patients with SMA type four (SMA4) suffer 
from milder motor impairment and are able to walk in adult 
years.
Patients with SMA have homozygous non-functional cop-
ies of the survival motor neuron 1 gene (SMN1) at locus 
5q13 [2]. Due to a duplication, the gene SMN2 exists in 
zero to five copies. The SMN2 gene is identical to the SMN1 
gene except for five base pairs [2]. Of these five, the single-
nucleotide base change in exon 7 causes alternative splicing 
and omission of exon 7 in SMN2, which in turn leads to a 
truncated form of the protein that is rapidly degraded [3]. 
Even so, approximately 5–10% of the SMN2 gene is still 
transcribed with exon 7 intact and a viable protein as result 
[2].
Nusinersen is an anti-sense oligonucleotide drug which 
prevents omission of exon 7 and subsequent loss of motor 
function by targeting the pre-mRNA of SMN2 [4, 5]. 
Thereby, the protein levels of SMN increases and motor neu-
rons are saved [6]. Two phase 3 clinical trials have shown 
the effectiveness of nusinersen. In the first trial, infants 
were included [4], and in the second, children with symp-
toms arising after the age of 6 months were included [5]. 
Regardless of onset, both trials demonstrated that the groups 
treated with nusinersen improved in motor function, whereas 
the children in the sham control groups deteriorated fur-
ther. However, a few children in both trials did not respond 
to treatment [4, 5]. Thus, it would be valuable to have a 
biomarker that could predict treatment response early on. 
Nusinersen was recently approved for treatment of SMA by 
the FDA and EMA.
Microtubule-associated protein tau and neurofilament 
light protein (NFL) are two neuron-specific structural pro-
teins. Tau is currently used as a clinical cerebrospinal fluid 
(CSF) biomarker of cortical neuronal degeneration in Alz-
heimer’s disease [7], but increased levels are also found with 
other types of neuronal damage, e.g., Creutzfeldt-Jakob dis-
ease and stroke [8]. NFL, on the other hand, together with its 
medium and heavy counterpart makes up the intermediate 
axonal filaments that determine axonal caliber and in part 
axonal velocity and is a well-established CSF biomarker for 
neurodegeneration across a wide range of neurodegenera-
tive diseases [9]. Another marker is GFAP, an intermediate 
filament present in astrocytes [10]. Our aim was to identify 
a biomarker to monitor response to nusinersen treatment in 
children with SMA type 1. For this, we measured CSF NFL, 
tau, and GFAP at baseline, and consecutively, in children 
with SMA at each timepoint, the drug was given.
Methods
Patients
Twelve children with SMA type 1 and two copies of the 
SMN2 gene were consecutively recruited in this single-
center study (Table  1). Motor function was measured 
with Children’s Hospital of Philadelphia Infant Test of 
Table 1  Demographics of SMA children
All values are mean ± SD. Numbers in brackets indicate range. The 






Age at onset (months) 2.2 ± 1.4 [0.3, 4]
Age at treatment (months) 14.4 ± 24.0 [1.2, 92.4]
Baseline Motor Score 24.3 ± 8.2 [11, 38]
NFL Levels (pg/mL)
 Dose 1 4598.3 ± 3398.1 (n = 12)
 Dose 2 4020.0 ± 2792.3 (n = 10)
 Dose 3 3173.3 ± 2067.0 (n = 9)
 Dose 4 1289.0 ± 1232.1 (n = 10)
 Dose 5 331.0 ± 223.9 (n = 10)
 Dose 6 161.2 ± 87.4 (n = 8)
 Dose 7 106.7 ± 47.3 (n = 3)
 Dose 8 215.0 ± 176.8 (n = 2)
Tau Levels (pg/mL)
 Dose 1 939.5 ± 551.1 (n = 12)
 Dose 2 802.6 ± 372.4 (n = 10)
 Dose 3 788.4 ± 368.7 (n = 9)
 Dose 4 528.1 ± 225.4 (n = 10)
 Dose 5 462.0 ± 260.9 (n = 10)
 Dose 6 454.6 ± 304.5 (n = 8)
 Dose 7 165.7 ± 57.5 (n = 3)
 Dose 8 166.0 ± 123.1 (n = 2)
GFAP Levels (pg/mL)
 Dose 1 235.8 ± 153.4 (n = 12)
 Dose 2 214.0 ± 89.1 (n = 10)
 Dose 3 228.9 ± 72.0 (n = 9)
 Dose 4 206.0 ± 137.4 (n = 10)
 Dose 5 147.0 ± 70.7 (n = 10)
 Dose 6 166.2 ± 95.5 (n = 8)
 Dose 7 130.0 ± 65.6 (n = 3)
 Dose 8 105.0 ± 49.5 (n = 2)
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Neuromuscular Disorders (CHOP INTEND) [11]. CHOP 
INTEND is a validated 16-item motor assessment designed 
specifically to evaluate the motor skills of infants with SMA; 
higher score indicates greater motor skill. The total CHOP 
INTEND score ranges 0–64. Motor function was assessed at 
start of treatment and thereafter at intervals of between 2 to 
6 months. Eleven children sampled for facial nerve palsy or 
to exclude meningitis or cerebellitis were used as controls. 
The study was approved by the Regional Ethics Committee 
in Gothenburg and all parents gave informed consent.
CSF analyses
CSF was sampled at baseline, and every time, the drug was 
given intrathecally at the Queen Silvia Children’s Hospi-
tal, Sahlgrenska University Hospital. Five mL of CSF was 
collected in polypropylene tubes, centrifuged (2000×g for 
10 min), and sent to the Clinical Neurochemistry Labora-
tory, Sahlgrenska University Hospital for storage at − 80 ℃ 
(within 2 h from sampling). Biomarker measurements were 
performed in clinical laboratory practice on a weekly basis 
using methods and procedures accredited by the Swed-
ish Board for Accreditation and Conformity Assessment 
(SWEDAC). The measurements were performed by board-
certified laboratory technicians who were blinded to clinical 
data. The first three doses were given every 2 weeks, the 
fourth dose 4 weeks later, and the following doses every 4 
months. NFL, tau, and GFAP concentrations were measured 
by enzyme-linked immunosorbent assays (the NF-light kit 
from UmanDiagnostics, Umeå, Sweden, the INNOTEST 
hTau kit from Fujirebio, Gent, Belgium and an in-house 
ELISA for GFAP [12]).
Statistical analysis
Patient #6 has continued treatment abroad after the first two 
doses. She increased to 24 points in CHOP INTEND after 
further dosing, but since we did not have access to the cor-
responding CSF samples, we have only included the baseline 
value in the analyses. We did not have access to CSF sample 
#3 for patient #9 due to the fact that this dose was given at 
the child’s local hospital. CSF sample #2 for patient #10 
was lost. Eight patients received six doses, three patients 
received seven doses, and two patients received eight doses 
of nusinersen before data cut (Tables 1 and 2).
Differences in baseline values of biomarkers between 
children with SMA and controls were analyzed with 
ANCOVA with age and sex as covariates.
Change in motor function as measured by the CHOP 
INTEND score was first analyzed independent of biomarker 
concentrations using linear mixed effects modelling with 
varying intercepts and varying slopes. Days since first nusin-
ersen treatment was used as the longitudinal dimension and 
individuals were treated as a random effect. Age at onset and 
age at treatment were included in separate interaction terms 
with the time dimension in order on to analyze their effects 
on both baseline and change in motor function. Spearman 
rank correlation coefficients were also calculated between 
intercepts/slopes and change in motor function.
Changes in CSF biomarker levels over time were ana-
lyzed using linear mixed effects modelling with varying 
intercepts and varying slopes, since we expected both base-
line levels and treatment effect to differ between individuals. 
Sex, age at disease onset, and age at treatment were included 
fixed effects in the model, while individuals were treated 
as a random effect. Dose number was used as the longitu-
dinal dimension for biomarker analysis, since dose timing 
was relatively standard across individuals and since models 
were adjusted for both age at onset and age at treatment. 
No adjustment for baseline biomarker levels was included, 
because CSF was not sampled before start of treatment. 
Mixed effects modelling was chosen due to its robustness 
to missing values and its ability to analyze both within- and 
between-subject characteristics of longitudinal data.
All analyses were performed using the R programming 
language, version 3.4, and the mixed effects modelling was 
Table 2  Individuals in the study and treatment regimen








1 SMA M 0 0.5 5
2 SMA M 1 2 5
3 SMA F 1 3 6
4 SMA F 1 3 8
5 SMA M 1 4 1
6 SMA F 2 18 2
7 SMA F 2 92 7
8 SMA F 3 7 6
9 SMA M 3 12 8
10 SMA M 4 14 6
11 SMA F 4 8 6
12 SMA F 4 9 6
1 Control F NA 36 NA
2 Control F NA 30 NA
3 Control F NA 4 NA
4 Control F NA 26 NA
5 Control M NA 3 NA
6 Control M NA 6 NA
7 Control M NA 18 NA
8 Control M NA 23 NA
9 Control M NA 10 NA
10 Control M NA 48 NA
11 Control M NA 96 NA
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specifically carried out using the nlme package, version 
3.1. All tests were two-sided with a statistical significance 
threshold of P < 0.05.
Results
One patient (#5) had severe symptoms already at onset of 
treatment and was converted to palliative care after only 
one dose given (Table 2). This patient was excluded from 
further analysis. The remaining 11 children were treated 
for a mean of 11 months, ranging from 2.5 to 19 months. 
Patient #7 was 92 weeks of age at start of treatment. The 
onset of disease was at 2 months of age. She was never able 
to sit independently and fulfilled all criteria for SMA type 1 
including having 2 SMN2 copies. The patient needed inten-
sive pulmonary care including non-invasive ventilation by 
nasal mask but never needed tracheostomy. She was often 
hospitalized, but survived due to intensive treatment. There 
was no significant difference in age (P = 0.24) or sex distri-
bution (P = 0.44) between the SMA and the control groups. 
Demographics are shown in Table 1.
Motor function improved for all patients who received 
more than one dose of nusinersen (patient #6 continued 
treatment abroad after dose two). The CHOP INTEND score 
increased 13 points in median (range 3–30 points), with an 
estimated improvement of 5.4 points per month accord-
ing to mixed effects model analysis (P < 0.0001, Fig. 1). 
In addition, change in CHOP INTEND score was inversely 
associated with age at disease onset (B = − 1.53, P = 0.01), 
while age at treatment had no effect on change in motor 
function (B = − 0.56, P = 0.35). Age at disease onset had no 
relationship with baseline CHOP INTEND score (B = -0.92, 
P = 0.13), while age at treatment had a significant inverse 
relationship (B = − 0.92, P = 0.03).
CSF NFL levels in the SMA children in our study were 
clearly increased at baseline compared with historical con-
trol data derived from children with benign medical his-
tory, including transient headache, diffuse pain, suspected 
infections, or habitual change in walking pattern, where 
brain imaging or CSF inflammatory and infectious markers 
were normal [13]. Baseline levels of NFL (4598 ± 981 vs 
148 ± 39, P = 0.001), tau (939 ± 159 vs 404 ± 86, P = 0.02), 
and GFAP (236 ± 44 vs 108 ± 26, P = 0.02) were also sig-
nificantly higher in the SMA children than the controls in 
our study.
NFL levels decreased over time by nusinersen treat-
ment [mean change = − 879.5 pg/mL per dose, 95% CI 
(− 1343.4, − 415.6), P = 0.0001] and typically normal-
ized ( < 380 pg/ml which is the cutoff in clinical routine 
for children [14]) between the fourth and fifth treatments 
(Fig.  2). Furthermore, earlier treatment initiation was 
associated with a larger decrease in NFL (rho = 0.67; 
P = 0.02) according to correlation analysis, with a nearly 
significant association according to mixed effects model-
ling (B = 154.8, P = 0.09). Tau levels also decreased over 
time [mean change = − 112.6 pg/mL per dose, 95% CI 
(− 206.7, − 18.6), P = 0.01, Fig. 2] with larger decreases 
in those with earlier disease onset (rho = 0.68, P = 0.02) 
and treatment initiation according to correlation analy-
sis (rho = 0.88, P = 0.0003) and mixed effects modelling 
(B = 73.02, P = 0.002). Individual changes in NFL and 
tau are shown in Fig. 3. Minor decreases were observed 
for GFAP [mean change = − 16.9 pg/mL per dose, 95% 
CI (− 22.8, − 11.2), P = 0.02; Fig. 2] but no association 
with either age at onset or age at treatment. Moreover, 
change in motor function correlated with change in NFL 
(rho = − 0.64, P = 0.03), tau (rho = − 0.85, P = 0.0008) but 
not GFAP.
Fig. 1  Change in motor function over time in children with SMA 
treated with nusinersen. Motor function improved in all patients who 
received more than one dose of nusinersen. The CHOP INTEND 
score increased 13 points in median (range 3–30 points) and 5.4 
points per month of treatment on average (P < 0.0001). Patient #6 
(only 1 CHOP INTEND value with baseline 15 points in the figure) 
has continued treatment abroad and increased to 24 points in CHOP 
INTEND after further dosing, but since we did not have access to 
the corresponding CSF samples, we have only included the baseline 
value in the figure and in calculations
Journal of Neurology 
1 3
Discussion
CSF levels of NFL normalized and correlated with motor 
improvement in children with the most severe form of SMA 
treated with nusinersen.
In ALS, motor neurons in the anterior horn of the spinal 
cord are destroyed leading to progressive loss of motor func-
tion and death [15]. Since motor neurons have the largest 
axons in the body and NFL is a subunit of neurofilaments, 
which is the main intermediate filament of axons, it is not 
surprising that CSF levels of NFL are increased in ALS 
as NFL is released from the injured and dying axons [16]. 
In some ways, SMA mirrors ALS as motor neurons also 
are lost in SMA. Nusinersen has been shown to ameliorate 
motor neuron decline in a mouse model of SMA [17]. Since 
NFL is an axonal marker [9] and the initial high levels of 
NFL that normalized by nusinersen treatment in combina-
tion with improved motor function suggest that the direct 
target of the disease, i.e., motor neurons, may be salvaged 
in children with SMA. However, future studies are needed 
to confirm this. A previous study of NFL in children with 
opsoclonus–myoclonus syndrome, non-inflammatory neuro-
logical disorders, and other inflammatory neurological dis-
orders showed that CSF levels of NFL do not correlate with 
age [18]. The lack of association between age and NFL was 
also observed in a study by Shahim et al. [13]. Furthermore, 
NFL decreased in all children who received more than one 
dose of nusinersen regardless of age in our study. In addi-
tion, we found significantly higher levels in children with 
SMA1 than in control children having an age span covering 
the SMA1 children, demonstrating that the decrease in NFL 
is caused by nusinersen treatment and not due to changes in 
CSF biomarker levels during normal development.
It is also apparent that the greatest benefit of the drug was 
found in children who received treatment earliest in their 
disease course, as the decrease in NFL was largest in those 
Fig. 2  Changes in CSF NFL, tau, and GFAP concentrations in chil-
dren with SMA by nusinersen treatment. a Changes in CSF NFL, 
tau, and GFAP concentrations by nusinersen treatment. NFL con-
centrations decreased significantly over time by nusinersen treatment 
[mean change = − 879.5 pg/mL per dose, 95% CI (− 1343.4, − 415.6), 
P = 0.0001] and normalized ( < 380  pg/ml) between the fourth and 
fifth treatments. Tau concentrations also decreased significantly over 
time [mean change = − 112.6  pg/mL per dose, 95% CI (− 206.7, 
− 18.6), P = 0.01] and minor but significant decreases were observed 
for GFAP [mean change = − 16.9  pg/mL per dose, 95% CI (− 22.8, 
− 11.2), P = 0.02]. b Changes in CSF NFL concentrations by age and 
nusinersen treatment. One patient (#5) had severe symptoms after 
receiving only one dose and was converted to palliative care before he 
died. This patient was excluded from further analysis. Each X denotes 
one of the 11 controls
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children. This suggests that treatment should commence as 
early as possible, since the longer treatment is delayed the 
worse effect on neurons. Thus, NFL may be used to identify 
children in need of rapid treatment and those requiring dose 
escalation. Since we observed such a rapid decline and nor-
malization in CSF levels of NFL after only a few treatments, 
NFL may be used as an early response marker guiding physi-
cians whether to continue treatment or not. This may also be 
important for parents, since they will know early on whether 
their child will benefit from the treatment or continue to 
deteriorate.
As mentioned above, the main consequence of SMA is 
loss of motor neurons, the axons of which are rich in NFL. 
Tau, on the other hand, is generally considered a cortical 
neuronal marker. Baseline levels of tau were significantly 
higher in children with SMA than in controls, indicating that 
children with SMA may also suffer from cortical neuronal 
damage. Furthermore, tau levels decreased by nusinersen 
treatment, indicating that the cortical neuronal damage is 
alleviated by nusinersen treatment. In addition, baseline lev-
els of GFAP were also increased in children with SMA com-
pared with controls, indicating that astrogliosis is increased 
in SMA which could be ameliorated by nusinersen, since the 
levels of GFAP were reduced by treatment.
All children in our study who received more than one 
dose of nusinersen improved in motor function and this 
improvement correlated with decreased CSF levels of NFL 
and tau. As we did not have any children on placebo or sham, 
we refer to the clinical trials of nusinersen which show that 
the natural course of the disease is progressive loss of motor 
function [4, 5]. Thus, nusinersen treatment was the reason 
behind the improvement in motor function also in our study.
Since both NFL and tau correlated with motor improve-
ment in children with SMA, one could argue that both could 
work as treatment markers in SMA. However, since the mag-
nitude of the decrease was so much larger for NFL than for 
tau and also that more children normalized, i.e., had levels 
below those set for clinical routine, in their NFL levels than 
Fig. 3  Individual changes in NFL and tau levels. One patient (#5) had severe symptoms after receiving only one dose and was converted to pal-
liative care before he died. This patient was excluded from further analysis
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for tau, NFL is in our view a better treatment marker than 
tau in SMA. In adults, NFL levels have been shown to be 
elevated in most forms of neurodegenerative diseases and 
also to correlate with clinical progression in Alzheimer’s 
disease, frontotemporal dementia, and Parkinson’s disease 
[19]. NFL concentrations also correlate with measures of 
cognition and brain atrophy in Huntington’s disease [20], 
indicating that it might be a promising marker for upcoming 
treatment regimes in diseases beside SMA.
The limitations of this study include a small study popu-
lation which could have influenced some of the results such 
as the non-significant result for change in motor function in 
relation to age at start of treatment. Still, we have included 
all available children with SMA type 1 in Sweden, since 
the drug was approved in late 2016. A strength of this study 
is that this was a single-center study and all children were 
treated by the same physician.
In conclusion, CSF levels of NFL normalized and cor-
related with motor improvement in children with SMA type 
1 treated with nusinersen. NFL may, therefore, be a novel 
biomarker to monitor treatment response to nusinersen early 
in the disease course. Furthermore, our data suggest that 
treatment should commence at the earliest timepoint to save 
as much of motor neurons as possible.
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